Literature DB >> 25005031

CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia.

Hongjie Shen1, Hongying Chao, Zixuan Ding, Yufeng Feng, Jiannong Cen, Jinlan Pan, Jun He, Ming Zhou, Zixing Chen, Suning Chen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25005031     DOI： 10.3109/10428194.2014.939963

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  10 in total

Review 1.  Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

Authors:  L Falchi; H M Kantarjian; S Verstovsek
Journal:  Leukemia       Date:  2017-05-22       Impact factor: 11.528

2.  A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.

Authors:  Yining Yang; Xiaorui Wang; Chun Wang; Youwen Qin
Journal:  Int J Hematol       Date:  2014-12-25       Impact factor: 2.490

3.  Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.

Authors:  Ipek Yonal-Hindilerden; Aynur Daglar-Aday; Basak Akadam-Teker; Ceylan Yilmaz; Meliha Nalcaci; Akif Selim Yavuz; Deniz Sargin
Journal:  J Blood Med       Date:  2015-06-01

4.  Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.

Authors:  Haixiu Guo; Xiuhua Chen; Ruiyuan Tian; Jianmei Chang; Jianlan Li; Yanhong Tan; Zhifang Xu; Fanggang Ren; Junxia Zhao; Jie Pan; Na Zhang; Xiaojuan Wang; Jianxia He; Wanfang Yang; Hongwei Wang
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

5.  JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.

Authors:  Bo Hyun Kim; Young-Uk Cho; Mi-Hyun Bae; Seongsoo Jang; Eul-Ju Seo; Hyun-Sook Chi; Yunsuk Choi; Dae-Young Kim; Jung-Hee Lee; Je-Hwan Lee; Kyoo-Hyung Lee; Young-Mi Park; Jong-Keuk Lee; Chan-Jeoung Park
Journal:  J Korean Med Sci       Date:  2015-06-10       Impact factor: 2.153

6.  Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms.

Authors:  João Agostinho Machado-Neto; Paula de Melo Campos; Dulcinéia Martins de Albuquerque; Fernando Ferreira Costa; Irene Lorand-Metze; Sara Terezinha Olalla Saad; Fabiola Traina
Journal:  Rev Bras Hematol Hemoter       Date:  2015-04-15

7.  Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.

Authors:  Sang Hyuk Park; Shine Young Kim; Sun Min Lee; Jongyoun Yi; In-Suk Kim; Hyung Hoi Kim; Chulhun Ludgerus Chang; Eun Yup Lee; Moo-Kon Song; Ho-Jin Shin; Joo Seop Chung
Journal:  Ann Lab Med       Date:  2015-02-12       Impact factor: 3.464

8.  [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center].

Authors:  M Y Li; H Y Chao; A N Sun; H Y Qiu; Z M Jin; X W Tang; Y Han; C C Fu; S N Chen; D P Wu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-04-14

9.  Genetic-pathologic characterization of myeloproliferative neoplasms.

Authors:  Yonggoo Kim; Joonhong Park; Irene Jo; Gun Dong Lee; Jiyeon Kim; Ahlm Kwon; Hayoung Choi; Woori Jang; Hyojin Chae; Kyungja Han; Ki-Seong Eom; Byung-Sik Cho; Sung-Eun Lee; Jinyoung Yang; Seung-Hwan Shin; Hyunjung Kim; Yoon Ho Ko; Haeil Park; Jong Youl Jin; Seungok Lee; Dong Wook Jekarl; Seung-Ah Yahng; Myungshin Kim
Journal:  Exp Mol Med       Date:  2016-07-22       Impact factor: 8.718

10.  ASXL1 mutations in Chinese patients with essential thrombocythemia.

Authors:  Yan-Bo Nie; Meng Sun; Colin K He; Man-Kai Ju; Fu-Ling Zhou; San-Yun Wu; Yi Zhou; Li Liu; Hui Shen; Ting-Ting Huang; Pan Liu; Ying Xu; Liang Shao; Xue-Lan Zuo
Journal:  Exp Ther Med       Date:  2018-03-09       Impact factor: 2.447
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.